COMPLERA Drug Patent Profile

When do Complera patents expire, and what generic alternatives are available?

Complera is a drug marketed by Gilead Sciences Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty-five patent family members in thirty-seven countries.

The generic ingredient in COMPLERA is emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Complera

Complera was eligible for patent challenges on May 20, 2015.

There have been sixteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for COMPLERA

International Patents:	55
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	6
Drug Prices:	Drug price information for COMPLERA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for COMPLERA
What excipients (inactive ingredients) are in COMPLERA?	COMPLERA excipients list
DailyMed Link:	COMPLERA at DailyMed

See drug prices for COMPLERA

Recent Clinical Trials for COMPLERA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ottawa Hospital Research Institute	Phase 3
Gilead Sciences	Phase 3
CIHR Canadian HIV Trials Network	Phase 3

See all COMPLERA clinical trials

Pharmacology for COMPLERA

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Non-Nucleoside Reverse Transcriptase Inhibitors Nucleoside Reverse Transcriptase Inhibitors

Paragraph IV (Patent) Challenges for COMPLERA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COMPLERA	Tablets	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	200 mg/25 mg/ 300 mg	202123	1	2015-05-20

US Patents and Regulatory Information for COMPLERA

COMPLERA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	AB	RX	Yes	Yes			Y

Expired US Patents for COMPLERA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011

International Patents for COMPLERA

When does loss-of-exclusivity occur for COMPLERA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering COMPLERA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20050092755	COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY
Japan	2011016847	NUCLEOTIDE ANALOG
Singapore	106656	NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD
Panama	8552901	DERIVADOS DE PIRIMIDINA INHIBIDORES DE VIH
Mexico	PA05007016	COMPOSICIONES Y METODOS PARA TERAPIA ANTIVIRAL DE COMBINACION. (COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY.)

Supplementary Protection Certificates for COMPLERA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1663240	CA 2015 00054	Denmark		PRODUCT NAME: KOMBINATION AF RILPIVIRIN ELLER ETN TERAPEUTISK AEKVIVALENT FORM DERAF, SOM ER BESKYTTET AF GRUNDPATENTET, SASOM ET FARMACEUTISK ACCEPTABELT SALT AF RILPIVIRIN, HERUNDER HYDROCHLORIDSALTET AF RILPIVIRIN, OG EMTRICITABIN; REG. NO/DATE: EU/1/11/737/001-002 20111128
0513200	300148	Netherlands		300148, 20110131, EXPIRES: 20160130
1663240	1690061-5	Sweden		PRODUCT NAME: A COMBINATION OF: RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIDE SALT OF RILPIVIRINE; AND TENOFOVIR ALAFENAMIDE, OR A PHARMCEUTICALLY ACCEPTABLE SALT THEREOF INCLUDING TENOFOVIR ALAFENAMIDE FUMARATE.; REG. NO/DATE: EU/1/16/1112 20160623
1663240	224 5022-2015	Slovakia		PRODUCT NAME: RILPIVIRINHYDROCHLORID/TENOFOVIRDIZOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128
1663240	93383	Luxembourg		PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, TEL QU'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, INCLUANT LE SEL CHLORHYDRATE DE RILPIVIRINE,EMTRICITABINE, ET TENOFOVIR ALAFENAMIDE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE DE TENOFOVIR ALAFENAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/16/1112 ODEFSEY - EMTRICITABINE

Market Dynamics and Financial Trajectory for COMPLERA

Last updated: January 14, 2026

Executive Summary

COMPLERA, a fixed-dose combination antiretroviral drug manufactured by Gilead Sciences, consolidates rilpivirine, emtricitabine, and tenofovir alafenamide into a single pill for the treatment of HIV-1. Since its FDA approval in 2017, COMPLERA has been positioned as a preferred regimen owing to its efficacy, safety profile, and convenient once-daily dosing. This analysis evaluates the evolving market landscape, competitive dynamics, revenue trajectory, and strategic factors influencing COMPLERA’s financial performance.

1. Overview of COMPLERA

Aspect	Details
Generic Name	Rilpivirine/Emtricitabine/Tenofovir Alafenamide
Brand Name	COMPLERA
Approval Date	November 2017 (FDA)
Indication	Treatment of HIV-1 infection in adults requiring antiretroviral therapy
Formulation	One tablet once daily
Manufacture	Gilead Sciences

2. Market Landscape and Dynamics

2.1. Global HIV/AIDS Market Overview

The global HIV drug market was valued at approximately $26.1 billion in 2022 and is projected to grow at a CAGR of 4.2% through 2028, supported by increased access programs and improved treatment adherence initiatives [1].

2.2. Key Drivers for COMPLERA’s Adoption

Driver	Impact
Efficacy & Safety Profile	High therapeutic efficacy, favorable safety/tolerability, minimal side effects
Convenience	Single-pill regimens enhance adherence
Guideline Endorsements	Recommendations from AASLD, WHO favor integrase inhibitor-based regimens
Pricing & Reimbursement	Competitive pricing facilitated by Gilead, reimbursement policies remain favorable

2.3. Competitive Landscape

Competitors	Key Attributes	Launch Year	Market Share (Estimate, 2022)
TRUVADA / DESCOVY (Gilead)	Similar fixed-dose combination with TDF/TAF variants	2004 / 2019	~65%
STUDY BRISAT (Gilead)	B/F/TAF as a successor but competes indirectly	2017	N/A
CABENUVA (Janssen)	2-drug long-acting injectable	2021	Emerging
Other oral regimens	Dolutegravir-based single-tablets, such as TRIUMEQ	2017	Remaining share

2.4. Market Penetration & Adoption Trends

While COMPLERA captures a significant segment of initial treatment, the advent of newer, long-acting injectables like CABENUVA is gradually shifting the landscape—targeting adherence-sensitive populations and those preferring less frequent dosing.

3. Financial Trajectory Analysis

3.1. Revenue Performance and Trends

Year	Estimated Global Revenue (USD billion)	Growth Rate	Notes
2017	$0.82	—	Launch year, initial uptake
2018	$1.05	28%	Growing acceptance, expanded access
2019	$1.23	17%	Increased use post-guideline updates
2020	$1.53	24%	COVID-19 impact mitigated, solid demand
2021	$1.68	10%	Market saturation, new competitors emerging
2022	$1.75	4.5%	Plateau stage, penetration limits

Note: These figures are based on estimated sales data, industry reports, and Gilead’s financial disclosures [2].

3.2. Factors Affecting Revenue Trajectory

Factor	Effect
Development of Long-acting Injectables	Potential cannibalization of oral regimen revenue
Guideline Shifts Toward INSTIs	Possible decline in COMPLERA use as INSTI-based single tablets preferred
Patent Life & Exclusivity	Patent expiry projected post-2028, opening room for generics or biosimilars
Pricing & Access Policies	Differential pricing and coverage in emerging markets affect global revenue
Market Penetration & Patient Demographics	Shift towards treatment initiation in diverse populations impacts future growth

3.3. Forecast Scenarios

Scenario	Assumption	Revenue Projection (2023-2027)
Optimistic (High growth)	Continued adherence, favorable guideline updates	CAGR 6.5%, reaching approx. $2.4 billion by 2027
Conservative	Market saturation, competition intensifies	CAGR 3-4%, reaching approx. $2 billion by 2027
Downturn	Entry of competing long-acting injectables, patent expiries	CAGR below 2%, potential decline post-2025 due to generics

(Sources: Industry reports, Gilead’s filings, analyst projections [3])

4. Strategic and Policy Factors

4.1. Regulatory Environment

• FDA Approvals: Regular updates to guidelines favor integrase inhibitors, mainly dolutegravir-based regimens.
• Patent Expiry: Expected post-2028 in key markets, opening generic opportunities.
• Pricing Policies: Governments and insurers in North America and Europe negotiate rebates; emerging markets see tiered pricing.

4.2. Market Access and Reimbursement

Region	Reimbursement Status	Challenges
North America	Broad coverage, Tier 2/3 formulary placement	Price pressure, Dirksen vs. restricted formularies
Europe	Varies by country; generally supportive	Budget constraints, access disparities
Emerging Markets	Tiered pricing, donor-funded programs	Limited awareness, procurement delays

4.3. R&D & Pipeline Considerations

Gilead continues investment in novel ARVs and combination therapies. The pipeline, including long-acting injectables and dual therapies, could influence COMPLERA’s market share negatively when new options gain approval.

5. Competitive Advantages and Challenges

Advantages	Challenges
Proven Efficacy & Safety	Competition from newer agents with improved tolerability
Single-tablet, Once-daily Dosing	Market shift toward long-acting formulations
Gilead's Established Market Presence	Patent expiration risks and biosimilar entries

6. Comparative Analysis: COMPLERA vs. Alternatives

Attribute	COMPLERA	TRUVADA/ DESCOVY	LONG-ACTING INJECTABLES
Formulation	Oral fixed-dose	Oral fixed-dose	Injectable (monthly/quarterly)
Dosing Frequency	Once daily	Once daily	Monthly or quarterly
Side Effect Profile	Favorable	Slightly different TDF/TDFa risk	Reduced daily adherence issues
Market Penetration	Strong initial, plateauing	Dominant in oral market	Growing but niche

7. Future Outlook and Trends

Trend	Implication
Transition to Long-acting Regimens	Likely to reduce COMPLERA’s market share but expand overall HIV treatment options
Enhanced Access Programs	Growth in emerging markets will sustain global revenues
Personalized Medicine & Biomarkers	Potential to optimize therapy choices, impacting COMPLERA demand
Patent Expirations & Generics	Generic competition post-2028 may significantly affect revenue

---

Key Takeaways

• Market Position: COMPLERA remains a key player in initial HIV therapy regimens, benefiting from convenience and efficacy.
• Revenue Outlook: Steady but plateauing, with projections indicating modest growth constrained by emerging long-acting options.
• Competitive Dynamics: The shift toward long-acting injectables like CABENUVA presents both a challenge and an opportunity for Gilead.
• Policy & Patent Risks: Patent expiry post-2028 could markedly impact exclusivity and revenues, emphasizing the importance of pipeline diversification.
• Global Access: Growth potential exists in emerging markets through tiered pricing and donation programs, though regulatory and infrastructural hurdles persist.

FAQs

1. How does COMPLERA compare to newer HIV regimens in terms of efficacy?
COMPLERA offers comparable efficacy to other first-line therapies, with a well-established safety profile. However, newer regimens such as dolutegravir-based fixed-dose combinations demonstrate faster resistance barriers and fewer side effects, leading clinicians to prefer them.

2. What are the key risks facing COMPLERA’s future revenue?
Major risks include patent expiries post-2028, the advent of long-acting injectables reducing oral regimen demand, and increasing competition from generics and biosimilars in mature markets.

3. How are global health policies influencing COMPLERA's market?
Policies advocating for treatment simplification, improved adherence, and access in low-resource settings can favor COMPLERA. Conversely, regulatory delays or price controls may restrict market penetration.

4. What is Gilead’s strategic response to emerging competition?
Gilead is investing in pipeline expansion with long-acting therapies like CABENUVA, seeking to complement its oral portfolio and retain market share through innovation.

5. How do patent expirations impact the availability of generics?
Post-2028 patent expiration could enable generic manufacturers to produce lower-cost versions, potentially reducing Gilead’s revenue and altering market dynamics.

---

References

[1] Global HIV Market Report 2022, IMS Health, 2022.
[2] Gilead Sciences Annual Report 2022.
[3] Pharma Intelligence Forecasts, 2023.